Online citations, reference lists, and bibliographies.
← Back to Search

Chemotherapy For Malignant Pleural Mesothelioma: Past Results And Recent Developments

S. Tomek, S. Emri, K. Krejcy, C. Manegold
Published 2003 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This review summarises the results of previously conducted clinical trials, and subsequently presents data arising from all phase II–III studies on chemotherapy of malignant pleural mesothelioma (MPM) published since the last relevant overview. While response rates exceeding 30% have barely been achieved with established cytotoxic drugs in MPM therapy, novel chemotherapeutic agents and their combinations appear more promising. This applies especially to the antimetabolites, and in particular to pemetrexed that produced response rates of up to 45% in combination with platinum compounds. Raltitrexed combined with oxaliplatin has also been shown to be effective, and gemcitabine–applied as a single agent or in combination with cisplatin–as well as vinorelbine appear to improve the quality of life in patients presenting with MPM. Data can now be more precisely analysed by increasingly implemented randomised studies, applying a standardised staging system, and distinguishing prognostic groups. While chemotherapy for MPM remains a challenging task, important steps have clearly been made in the past years to combat this aggressive disease. The publication of pemetrexed with cisplatin phase III results in a peer-reviewed journal may soon establish a standard of care.
This paper references
10.1016/0169-5002(96)00584-3
Two dose levels of ifosfamide in malignant mesothelioma.
F. Içli (1996)
10.1183/09031936.96.09122565
Effect of hemithorax irradiation alone or combined with doxorubicin and cyclophosphamide in 47 pleural mesotheliomas: a nonrandomized phase II study.
C. J. Lindén (1996)
10.1378/CHEST.113.1_SUPPLEMENT.66S
A review of chemotherapy trials for malignant mesothelioma.
C. Ryan (1998)
CPT-11 in Malignant Mesothelioma: A Phase II Trial by the Cancer and Leukemia Group B (CALGB 9733)
HL Kindler (2000)
Phase II trial of mitomycin in malignant mesothelioma.
D. Bajorin (1987)
Phase II Trial of ZD0473 in Patients with Mesothelioma Relapsing After One Prior Chemotherapy Regimen
G Giaccone (2001)
Paclitaxel and carboplatin for malignant mesothelioma
ME Bednar (1999)
Phase II trial of diaziquone in malignant mesothelioma.
R. Eagan (1986)
10.1007/BF00685720
Carboplatin in malignant mesothelioma: A phase II study of the cancer and leukemia Group B
N. Vogelzang (2004)
10.1016/S0936-6555(05)80582-5
The role of palliative radiotherapy in malignant mesothelioma.
D. Bissett (1991)
10.1200/JCO.1996.14.3.878
Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a.
P. Soulié (1996)
10.1002/1097-0142(19941101)74:9<2460::AID-CNCR2820740912>3.0.CO;2-N
Intrapleural treatment with recombinant gamma‐interferon in early stage malignant pleural mesothelioma
C. Boutin (1994)
10.1016/S0169-5002(00)80056-2
Multicenter phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma (MPM)
J. Haarst (2000)
10.1177/030089169808400509
Combined Epirubicin and Interleukin-2 Regimen in the Treatment of Malignant Mesothelioma: A Multicenter Phase II Study of the Italian Group on Rare Tumors
S. Bretti (1998)
10.1016/S0169-5002(99)00030-6
Ifosfamide in malignant mesothelioma: a phase II study.
M. Andersen (1999)
10.1097/00002371-199809000-00007
Intralesional Cytokine Therapy in Cancer: A Pilot Study of GM‐CSF Infusion in Mesothelioma
J. A. Davidson (1998)
Chemotherapy for malignant mesothelioma.
R. Taub (1997)
Immunotherapy with BCG vaccine in 30 cases of mesothelioma.
I. Webster (1982)
Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma
HG Bischoff (1998)
10.1002/1097-0142(19890315)63:6<1084::AID-CNCR2820630608>3.0.CO;2-U
Activity of pirarubicin (4′‐o‐tetrahydropyranyladriamycin) in malignant mesothelioma
Kasi S. Sridhar (1989)
Phase II trial of vindesine in malignant pleural mesothelioma.
C. Boutin (1987)
10.1200/JCO.1992.10.5.824
Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
K. Mattson (1992)
10.1097/00000421-199402000-00018
Recombinant Interferon Alpha‐2b in the Treatment of Diffuse Malignant Pleural Mesothelioma
A. Ardizzoni (1994)
10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.0.CO;2-S
A phase II study of gemcitabine in patients with malignant pleural mesothelioma
J. van Meerbeeck (1999)
10.1002/(SICI)1097-0142(19991115)86:10<1985::AID-CNCR15>3.0.CO;2-H
Edatrexate (10‐ethyl‐deaza‐aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma
H. Kindler (1999)
10.1002/1097-0142(19851101)56:9<2170::AID-CNCR2820560905>3.0.CO;2-L
A prospective study of detorubicin in malignant mesothelioma
Nicolas Colbert (1985)
10.1136/thorax.55.9.725a
Malignant mesothelioma: predictors of prognosis and clinical trials
J. Steele (2000)
10.1007/BF00254253
A phase II study of m-AMSA in patients with malignant mesothelioma
G. Falkson (2004)
10.1016/S0169-5002(00)80054-9
Phase II trial of vinorelbine and oxaliplatin in patients with malignant pleural mesothelioma
J. Steele (2000)
10.1016/S0022-5223(98)70274-0
Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma.
H. Pass (1998)
10.1016/0360-3016(90)90330-M
Physical aspects of external beam radiotherapy for the treatment of malignant pleural mesothelioma.
M. Soubra (1990)
10.1093/OXFORDJOURNALS.ANNONC.A058941
A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma.
L. Dirix (1994)
10.1164/AJRCCM/143.2.408
Cellular and molecular basis of the asbestos-related diseases.
W. Rom (1991)
10.1002/AJIM.4700190310
Fibrous zeolite (erionite)-related diseases in Turkey.
Baris Yi (1991)
10.1097/00000421-200104000-00009
Combination Chemotherapy With Mitoxantrone, Methotrexate, and Mitomycin (MMM Regimen) in Malignant Pleural Mesothelioma: A Phase II Study
C. Pinto (2001)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
The North-Eastern Italian Oncology Group (GOCCNE)-Mesothelioma Committee
Malignant mesothelioma in women.
V. Roggli (1997)
10.1200/JCO.1987.5.1.86
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
M. Samson (1987)
10.3816/CLC.2004.N.020
Docetaxel for malignant mesothelioma: phase II study of the Eastern Cooperative Oncology Group.
C. Belani (2004)
10.1023/A:1011139918558
Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma.
J. Steele (2001)
10.1016/S0959-8049(01)80558-X
Phase II study of ALIMTA (pemetrexed disodium, MTA) single agent in patients with malignant pleural mesothelioma
G. Scagliotti (2001)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
10.1002/1097-0142(19821001)50:7<1245::AID-CNCR2820500704>3.0.CO;2-H
High‐dose methotrexate with citrovorum factor and vincristine in the treatment of malignant mesothelioma
N. Dimitrov (1982)
10.1177/030089169107700112
Epirubicin in the Treatment of Malignant Mesothelioma: A Phase II Cooperative Study
M. Magri (1991)
10.1111/J.1445-5994.1993.TB04727.X
Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study.
J. Upham (1993)
10.1016/S0022-5223(96)70342-2
The importance of surgical staging in the treatment of malignant pleural mesothelioma.
V. Rusch (1996)
10.1016/0277-5379(89)90141-7
A phase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma.
J. Carmichael (1989)
10.1038/sj.bjc.6600505
A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma
A. Nowak (2002)
Effect of interferon-alpha 2a on malignant mesothelioma.
T. Christmas (1993)
10.1002/1097-0142(19910615)67:12<2984::AID-CNCR2820671208>3.0.CO;2-Q
Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An italian lung cancer task force (FONICAP) phase II study
A. Ardizzoni (1991)
10.1016/S0959-8049(00)00139-8
Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma.
K. Fizazi (2000)
Randomised phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia
AP Chahinian (1993)
10.1093/jnci/78.4.785-f
European Organization for Research and Treatment of Cancer.
H. Fukuda (2000)
Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma.
B. Cantwell (1986)
10.1093/JNCI/78.6.1053
Demographic patterns for mesothelioma in the United States.
R. Connelly (1987)
10.1002/(SICI)1097-0142(19970601)79:11<2237::AID-CNCR23>3.0.CO;2-W
Dihydro‐5‐azacytidine in malignant mesothelioma
N. Vogelzang (1997)
10.1002/1097-0142(19840915)54:6<961::AID-CNCR2820540602>3.0.CO;2-B
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single‐agent 5‐fluorouracil and adriamycin
V. Harvey (1984)
Randomised trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma
PG Sorensen (1985)
10.1038/bjc.1995.501
Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.
S. H. Goey (1995)
10.1038/sj.bjc.6690597
High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma
M. Halme (1999)
10.1016/S0959-8049(97)00263-3
Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma.
L. Trandafir (1997)
10.1093/JNCI/48.3.797
Mechanisms of mesothelioma induction with asbestos and fibrous glass.
M. Stanton (1972)
10.1038/bjc.1992.200
High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study.
O. Solheim (1992)
10.1093/jnci/92.6.496
Response: More About: Cell and Molecular Biology of Simian Virus 40: Implications for Human Infections and Disease.
J. Butel (2000)
10.1016/0277-5379(91)90430-L
Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group.
F. J. van Breukelen (1991)
10.1016/0169-5002(94)90550-9
Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma.
N. Tsavaris (1994)
Edatrexate ( 10ethyldeazaaminopterin ) ( NSC # 626715 ) with or without leucovorin rescue for malignant mesothelioma
HL Kindler (1999)
Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent.
D. B. Mendel (2000)
SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
T. Fong (1999)
10.1038/sj.bjc.6690650
VEGF and VEGF type C play an important role in angiogenesis and lymphangiogenesis in human malignant mesothelioma tumours
Y. Ohta (1999)
10.1089/JIR.1988.8.813
Effect of recombinant interferon-beta ser on primary human tumor colony-forming units.
D. V. Von Hoff (1988)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1093/JNCI/58.3.587
Carcinogenicity of fibrous glass: pleural response in the rat in relation to fiber dimension.
M. Stanton (1977)
10.1007/BF00944192
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma
G. Falkson (2004)
Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study.
E. Eisenhauer (1986)
Gemcitabine ( Gemzar s ) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma
HG Bischoff (1998)
10.1097/00001813-200004000-00005
Docetaxel and irinotecan (CPT-11) in the treatment of malignant pleural mesothelioma - a feasibility study
A. Knuuttila (2000)
10.1093/OXFORDJOURNALS.ANNONC.A058159
Treatment of malignant mesothelioma with epirubicin and ifosfamide: a phase II cooperative study.
M. Magri (1992)
10.1016/S0169-5002(00)00166-5
Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.
H. Kindler (2001)
10.1002/(SICI)1097-0142(19990615)85:12<2577::AID-CNCR13>3.3.CO;2-J
A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
J. Van Meerbeeck (1999)
10.1016/S0959-8049(97)00183-4
Etoposide in malignant pleural mesothelioma: two phase II trials of the EORTC Lung Cancer Cooperative Group.
T. Sahmoud (1997)
10.1136/bmj.285.6342.603
Mesotheliomas and asbestos type in asbestos textile workers: a study of lung contents.
J. Wagner (1982)
10.3109/07357909909021421
A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma.
E. O’Reilly (1999)
10.1016/0002-9343(94)90307-7
Malignant mesothelioma following radiation therapy.
J. Hofmann (1994)
10.1002/(SICI)1097-0142(19981115)83:10<2099::AID-CNCR8>3.0.CO;2-3
Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma
P. Astoul (1998)
10.1002/1097-0142(19900815)66:4<651::AID-CNCR2820660408>3.0.CO;2-3
A phase II study of pirarubicin in malignant pleural mesothelioma
E. Kaukel (1990)
10.1097/00000421-199812000-00017
Phase II trial of topotecan for the treatment of mesothelioma.
A. Maksymiuk (1998)
10.1081/CNV-120023766
Cisplatin and Irinotecan (CPT-11) for Peritoneal Mesothelioma
D. T. Le (2003)
Vindesine in the treatment of malignant mesothelioma: a phase II study.
D. Kelsen (1983)
10.1023/A:1008328605413
Randomised phase II study of cisplatin-etoposide versus infusional carboplatin in advanced non-small-cell lung cancer and mesothelioma.
S. White (2000)
Augmentation of activity of cis-diamminedichloroplatinum(II) and mitomycin C by interferon in human malignant mesothelioma xenografts in nude mice.
N. Sklarin (1988)
10.1378/CHEST.116.2.504
Advances in the treatment of malignant pleural mesothelioma.
D. Sterman (1999)
10.1002/1097-0142(19831201)52:11<1981::AID-CNCR2820521102>3.0.CO;2-P
Malignant mesothelioma. The eastern cooperative oncology group (ECOG) experience
H. Lerner (1983)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Preliminary results of a phase I study with MTA (LY231514) in combination with cisplatin in patients with solid tumors.
R. Thödtmann (1999)
10.1097/00000421-198302000-00011
Combination chemotherapy for advanced sarcomas of bone and mesothelioma utilizing rubidazone and DTIC: a Southwest Oncology Group Study.
B. Zidar (1983)
10.1159/000216501
Phase-II study with the combination of cisplatin and doxorubicin in advanced malignant mesothelioma of the pleura.
H. Henss (1988)
10.1007/BF00173653
A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma
E. Eisenhauer (2004)
10.1002/(SICI)1096-9098(199802)67:2<104::AID-JSO6>3.0.CO;2-E
Effectiveness of cisplatin, paclitaxel, and suramin against human malignant mesothelioma xenografts in athymic nude mice
A. Chahinian (1998)
10.1023/A:1006421706540
Phase II Study of Intravenous Doxil® in Malignant Pleural Mesothelioma
Y. Oh (2004)
10.1016/S0140-6736(95)90462-X
Continuing increase in mesothelioma mortality in Britain
J. Peto (1995)
10.1007/BF00273404
Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma
E. Mbidde (2004)
10.1006/SCBI.2000.0347
SV40 and the pathogenesis of mesothelioma.
P. Rizzo (2001)
A phase II study of pirarubicin in malignant pleural mesothelioma Vindesine in the treatment of malignant mesothelioma: a phase II study
E Kaukel (1983)
Chemotherapy for malignant pleural mesothelioma S Tomek et al
10.1200/JCO.1996.14.7.2098
Malignant mesothelioma following treatment for Hodgkin's disease.
L. Weissmann (1996)
10.1016/S0959-8049(01)80092-7
Sentinel node (SN) biopsy can safely replace axillary node sampling for staging early breast cancer
T. Agarwal (2001)
10.1200/JCO.1993.11.8.1559
Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B.
A. Chahinian (1993)
10.1093/OXFORDJOURNALS.ANNONC.A058735
Oral etoposide in the treatment of malignant mesothelioma. A phase II study.
L. Tammilehto (1994)
10.1016/0360-3016(87)90173-8
Technique for external beam treatment for mesothelioma.
G. Kutcher (1987)
10.1200/JCO.2002.10.073
Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma.
A. Hughes (2002)
10.1016/0360-3016(84)90050-6
Pleurectomy and intraoperative brachytherapy and postoperative radiation in the treatment of malignant pleural mesothelioma.
B. Hilaris (1984)
Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.
P. Sørensen (1985)
Randomised phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B
AP Chahinian (1993)
10.3109/07357909609018904
Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers.
B. Mossman (1996)
10.1093/OXFORDJOURNALS.ANNONC.A059253
Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma.
A. Planting (1995)
10.5555/URI:PII:0093775481900439
Chemotherapy in the treatment of malignant mesothelioma.
J. Aisner (1981)
10.1016/S0169-5002(98)90133-7
Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV.
S. Aversa (1999)
10.1002/(SICI)1097-0142(19970515)79:10<1897::AID-CNCR9>3.0.CO;2-D
Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma
M. Pennucci (1997)
10.1200/JCO.1999.17.1.25
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
10.1016/0002-9343(80)90103-5
Multimodality therapy for malignant mesothelioma based on a study of natural history.
K. H. Antman (1980)
10.1023/A:1026438215309
High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234.
N. Vogelzang (1999)
Dihydro - 5azacytidine and cisplatin in the treatment of malignant mesothelioma : a phase II study by the Cancer and Leukemia Group B
BL Samuels (1998)
Increased epidermal growth factor-receptor protein in a human mesothelial cell line in response to long asbestos fibers.
J. Pache (1998)
Benign and malignant pleural mesothelioma.
K. Antman (1985)
10.1200/JCO.1994.12.7.1436
Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study.
N. Vogelzang (1994)
10.1023/A:1008236010868
Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma.
George W. Middleton (1998)
Dihydro-5azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity
NJ Vogelzang (1997)
Phase II study of intravenous Doxil in malignant pleural mesothelioma Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma
Y Oh (1998)
10.1023/A:1008346925273
Caelyx in malignant mesothelioma: a phase II EORTC study.
P. Baas (2000)
10.1200/JCO.1983.1.11.695
Malignant mesothelioma following radiation exposure.
K. H. Antman (1983)
10.1002/1097-0142(19951201)76:11<2230::AID-CNCR2820761108>3.0.CO;2-2
Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma
D. Shin (1995)
10.1038/sj.onc.1201375
Simian virus 40, poliovaccines and human tumors: a review of recent developments
M. Carbone (1997)
10.1016/S0169-5002(96)00619-8
Studies concerning high dose ifosfamide to patients suffering from malignant mesothelioma.
A. Krarup-Hansen (1996)
10.1002/1097-0142(19921115)70:10<2547::AID-CNCR2820701025>3.0.CO;2-F
A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma: A southwest oncology group study
B. Zidar (1992)
Phase II trial of acivicin in malignant mesothelioma.
G. Falkson (1987)
10.1378/CHEST.116.2.391
Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma.
M. Metintas (1999)
10.1002/(SICI)1097-0142(19980415)82:8<1578::AID-CNCR21>3.0.CO;2-0
Dihydro‐5‐azacytidine and cisplatin in the treatment of malignant mesothelioma
B. Samuels (1998)
10.1089/JIR.1990.10.531
Phase II Evaluation of Recombinant Interferon-β (LFN-βser) in Patients with Diffuse Mesothelioma: A Southwest Oncology Group Study
D. V. Hoff (1990)
10.1007/BF00175408
Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: A Southwest Oncology Group study
J. D. Cowan (2004)
10.1007/BF00263135
A phase II study of vincristine in malignant mesothelioma — a negative report
G. Mårtensson (2004)
10.1007/BF00175403
A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: A Southwest Oncology Group Study
B. Zidar (2004)
10.1038/bjc.1996.465
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
J. Van Meerbeeck (1996)
10.1016/S0169-5002(00)80058-6
Taxotere in malignant pleural mesothelioma. A phase II clinical trial
D. Vorobiof (2000)
A phase II study of VP-16 and cisplatin in patients with unresectable maignant mesothelioma. An NCI Canada Clinical Trials Group Study
EA Eisenhauer (1988)
A phase II evaluation of ifosfamide and mesna in unresectable diffuse malignant mesothelioma
BL Zidar (1992)
10.1002/1097-0142(20010801)92:3<650::AID-CNCR1366>3.0.CO;2-0
Combined regimen of cisplatin, doxorubicin, and α‐2b interferon in the treatment of advanced malignant pleural mesothelioma
H. Parrà (2001)
10.1038/sj.bjc.6600118
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma
J. van Haarst (2002)
10.1002/(SICI)1097-0142(19990601)85:11<2375::AID-CNCR12>3.0.CO;2-E
Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma
T. Nakano (1999)
10.1200/JCO.1990.8.1.151
Phase II trial of carboplatin in the management of malignant mesothelioma.
D. Raghavan (1990)
10.1016/S0169-5002(00)00192-6
Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
B. Castagneto (2001)
Chemotherapy for malignant mesothelioma with adriamycin and continuous infusion of 5-azacytidine.
A. Chahinian (1978)
10.1200/JCO.2000.18.23.3912
Phase II study of vinorelbine in patients with malignant pleural mesothelioma.
J. Steele (2000)
10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q
New molecular and epidemiological issues in mesothelioma: Role of SV40
M. Carbone (1999)
10.1159/000227363
Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon.
S. Tansan (1994)
10.1177/030089169207800607
Mitomycin C and Vindesine: An Ineffective Combination Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
C. Gridelli (1992)
10.1093/JNCI/80.9.698-A
Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna.
A. Alberts (1988)
Phase II trial of high-dose cisplatin in patients with malignant mesothelioma.
D. Mintzer (1985)
10.1023/A:1008216716778
Prevention of hepatitis development by interferon-alpha in HBV carriers treated with intensive chemotherapy: a pilot study.
K. Kumagai (1998)



This paper is referenced by
10.1016/J.LUNGCAN.2006.01.002
Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1).
C. Pinto (2006)
10.3816/CLC.2004.S.004
Pemetrexed alone and in combination with platinum compounds in the management of malignant mesothelioma.
Harit Suwanrusme (2004)
10.1158/1535-7163.MCT-07-2132
Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodies
F. An (2008)
10.1016/J.LUNGCAN.2005.03.022
Overview on ongoing or planned clinical trials in Europe.
A. Favaretto (2005)
10.1200/JCO.2007.12.5641
Phase II study of vinflunine in malignant pleural mesothelioma.
D. Talbot (2007)
10.1183/09031936.00090407
Asbestos induces doxorubicin resistance in MM98 mesothelioma cells via HIF-1α
C. Riganti (2008)
but not the cytoskeleton
Kenjirou Hara (2011)
10.1517/14728210903074563
Malignant pleural mesothelioma: current treatments and emerging drugs
C. Belli (2009)
10.1007/978-3-319-96244-3_5
Chemotherapy and Standard Treatment Options
M. Hesdorffer (2019)
10.1016/S1556-0864(15)31537-9
Newer Issues in Mesothelioma Chemotherapy
N. Vogelzang (2006)
10.1586/14737140.5.2.231
Pemetrexed–cisplatin combination in mesothelioma
M. Reck (2005)
10.1038/sj.bjc.6601707
α-Tocopheryl succinate and TRAIL selectively synergise in induction of apoptosis in human malignant mesothelioma cells
M. Tomasetti (2004)
10.1016/j.cllc.2013.04.013
ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.
S. Ting (2013)
10.1016/J.LUNGCAN.2006.11.005
A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 A single institution experience.
M. Metintas (2007)
10.18632/oncotarget.16398
Folic acid phenotype (FAP) is a superior biomarker predicting response to pemetrexed-based chemotherapy in malignant pleural mesothelioma
F. Mairinger (2017)
10.1007/0-387-28274-2_40
Second-Line Chemotherapy
N. Pavlakis (2005)
10.1158/1535-7163.MCT-06-0073
Therapeutic potential of antisense oligodeoxynucleotides to down-regulate thymidylate synthase in mesothelioma
Janet Flynn (2006)
10.2482/HAIGAN.47.137
A Case of Primary Pericardial Mesothelioma Surviving for a Long-period After Local Hyperthermochemotherapy and Systemic Chemotherapy
Y. Ozawa (2007)
10.1179/oeh.2004.10.1.26
Malignant Pleural Mesothelioma—An Update
D. Stewart (2004)
10.1016/J.LUNGCAN.2006.04.014
Divided dose of cisplatin combined with gemcitabine in malignant mesothelioma.
G. Utkan (2006)
10.1002/CNCR.20924
Tumor necrosis factor enhances SN38-mediated apoptosis in mesothelioma cells: The role of nuclear factor-κB pathway activation
P. Russo (2005)
10.1007/978-0-387-68113-9_75
Pleura: Anatomy, Physiology, and Disorders
J. Friedberg (2008)
10.18632/oncotarget.24962
Immunohistochemically detectable metallothionein expression in malignant pleural mesotheliomas is strongly associated with early failure to platin-based chemotherapy
F. Mairinger (2018)
10.5833/JJGS.42.127
A Case of Localized Peritoneal Malignant Mesothelioma with Lymph Nodes Metastases
Daisuke Inagaki (2009)
10.18632/oncotarget.7666
microRNAs are differentially regulated between MDM2-positive and negative malignant pleural mesothelioma
R. F. Walter (2016)
10.1016/j.jtcvs.2015.02.020
Paclitaxel-loaded expansile nanoparticles enhance chemotherapeutic drug delivery in mesothelioma 3-dimensional multicellular spheroids.
Hong-yi Lei (2015)
10.1007/s12199-007-0016-7
Current therapies for malignant pleural mesothelioma
T. Nakano (2008)
Investigating heterogeneity of growth and drug response in mesotheliomas
Roxanne Otadoy (2013)
10.1517/14728214.12.1.127
Emerging drugs for mesothelioma
G. Scagliotti (2007)
10.1201/9781420026399.ch6
Vitamin E analogs as anticancer agents
J. Neuzil (2006)
10.1586/14737140.2016.1162100
A catalogue of treatment and technologies for malignant pleural mesothelioma
Laurel M. Schunselaar (2016)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
See more
Semantic Scholar Logo Some data provided by SemanticScholar